These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
615 related articles for article (PubMed ID: 16189912)
21. Clinical trials face heightened scrutiny as science and commerce appear to merge. Lorman AJ J Biolaw Bus; 2001; 4(4):23-32. PubMed ID: 12751494 [TBL] [Abstract][Full Text] [Related]
22. Researcher liability for negligence in human subject research: informed consent and researcher malpractice actions. Jansson RL Wash Law Rev; 2003 Feb; 78(1):229-63. PubMed ID: 15732212 [TBL] [Abstract][Full Text] [Related]
23. How institutional review boards (IRBs) can handle adverse event reports. Maloney DM Hum Res Rep; 2006 Jan; 21(1):1-3. PubMed ID: 16789305 [No Abstract] [Full Text] [Related]
24. Informed consent process is deemed "legally and ethically invalid" by witness. Maloney DM Hum Res Rep; 1995 Jan; 10(1):4-5. PubMed ID: 11660008 [No Abstract] [Full Text] [Related]
25. The role of institutional review boards in protecting human subjects: are we really ready to fix a broken system? Beh HG Law Psychol Rev; 2002; 26(1):1-47. PubMed ID: 16514756 [No Abstract] [Full Text] [Related]
26. Protecting research subjects--what must be done. Shalala D N Engl J Med; 2000 Sep; 343(11):808-10. PubMed ID: 10984573 [No Abstract] [Full Text] [Related]
27. Research administrator should not serve on institutional review board. Maloney DM Hum Res Rep; 2002 Apr; 17(4):6-7. PubMed ID: 12374181 [No Abstract] [Full Text] [Related]
28. IRBs and monitoring the safety of clinical trials. Maloney DM Hum Res Rep; 2003 Jan; 18(1):3. PubMed ID: 12755095 [No Abstract] [Full Text] [Related]
29. Human subject protections in the United States: perspectives from the Office for Protection from Research Risks. Russell-Einhorn M; Ellis GB J Biolaw Bus; 1998; 1(2):36-8. PubMed ID: 12739540 [TBL] [Abstract][Full Text] [Related]
30. Case study: agency says institutional review board (IRB) did not fulfill duties so agency investigation expands. Maloney DM Hum Res Rep; 2006 Apr; 21(4):6-7. PubMed ID: 16832919 [No Abstract] [Full Text] [Related]
32. Institutional review boards not paying enough attention to active research projects. Maloney DM Hum Res Rep; 1998 Nov; 13(11):1-2. PubMed ID: 11657741 [No Abstract] [Full Text] [Related]
33. Recurrent issues in the review of medical research on human subjects. Moore DL Albany Law J Sci Technol; 1991; 1():1-33. PubMed ID: 16296123 [No Abstract] [Full Text] [Related]
34. Institutional review boards and the privacy of human research subjects. Maloney DM Hum Res Rep; 2002 Aug; 17(8):1-2. PubMed ID: 12731492 [No Abstract] [Full Text] [Related]
35. IRBs and continuing review: regulatory interference or vital safeguard? McBride LC; Yessian MR Food Drug Cosmet Med Device Law Dig; 1999 Mar; 16(1):13-7. PubMed ID: 12784812 [No Abstract] [Full Text] [Related]
37. Regulating clinical research: informed consent, privacy, and IRBs. Hoffman S Cap Univ Law Rev; 2003; 31(1):71-91. PubMed ID: 15295833 [No Abstract] [Full Text] [Related]
38. Time for new rules on human subjects research? Dresser R Hastings Cent Rep; 1998; 28(6):23-4. PubMed ID: 9868606 [No Abstract] [Full Text] [Related]
39. Protecting vulnerable research subjects: practical realities of institutional review board review and approval. Wichman A J Health Care Law Policy; 1998; 1(1):88-104. PubMed ID: 15573431 [No Abstract] [Full Text] [Related]
40. Ethical oversight of research in developing countries. Kass N; Dawson L; Loyo-Berrios NI IRB; 2003; 25(2):1-10. PubMed ID: 12833901 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]